- 42 Actavis products recommended Reykjavik, Iceland, 30 April 2007 -- Actavis Group (OMX: ACT), the international generic pharmaceuticals company, today announced that its subsidiary in Germany has signed a partnership contract with the German VdAK / AEV association. The association represents seven health insurance funds in Germany that provide coverage for around 8.7 million people across the country. Under the terms of the contract, Actavis will supply a wide range of products used for the treatment of chronic and acute illnesses. The agreement follows the signing with the largest health insurance provider in Germany, Allgemeine Ortskrankenkassen ("AOK") in March, where Actavis was also selected in a preferred partnership agreement. The association has only selected Actavis for all of the 42 products, whose products will be listed and recommended for the patients of the participants. The new agreement is valid for one year. Participants will include the following: * DAK - German employee health insurance company, Hamburg * HEK - Hanseatic health insurance company, Hamburg * HMK - Hamburg Munich health insurance company, Hamburg * Hkk - Commercial health insurance company, Bremen * GEK -Gmünder private health insurance fund, Swabian Gmünd * HZK - Health insurance company for professionals in building industry and wood processing, Hamburg * KEH - Private health insurance fund - Heusenstamm Svend Andersen, Executive VP for Western Europe, the Middle-East and Africa, said: "Our agreement with the VdAK/AEV association is recognition for our business in Germany. Our growing presence, combined with a dynamic pipeline of products will benefit around 9 million German health insurance policy holders going forward and we are excited to start this new business relationship. This means that German doctors and pharmacists will be encouraged to recommend products from Actavis, supporting our sales growth in the market" About Actavis Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in over 30 countries, with 11,000 employees. The company's market capitalization is approximately EUR3 billion (US$3.8 billion) and is listed in the OMX stock exchange in Iceland. Actavis expects 2007 sales to total EUR1.6 billion, with approximately 8% of sales coming from Germany, the Group's third largest market. Over 10 new product launches are expected from Actavis in Germany in 2007. The company's German operations are located in Langenfeld. More information about Actavis can be found on www.actavis.com. Inquiries Halldor Kristmannsson Vice President of Corporate Communications & IR Tel: (+354) 535 2325 / 840 3425 E-mail: [email protected]